/
GH
$150.13-$3.61 (-2.35%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$19.8B
133M shares
52-week range
$40.36 – $153.95
97% from low
Sector
SERVICES-MEDICAL LABORATORIES
Exchange
NASDAQ
CS
Borrow rate
0.27%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$23.28
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $90.6M | $214.4M | $286.7M | $373.7M | $449.5M | $563.9M | $739.0M | $982.0M |
| Cost of revenue | $43.2M | $70.7M | $92.5M | $122.9M | $156.3M | $227.1M | $289.8M | $349.0M |
| Gross profit | $47.4M | $143.7M | $194.2M | $250.7M | $293.2M | $336.9M | $449.2M | $633.0M |
| Gross margin | 52.3% | 67.0% | 67.7% | 67.1% | 65.2% | 59.7% | 60.8% | 64.5% |
| R&D | $50.7M | $86.3M | $149.9M | $263.2M | $373.8M | $367.2M | $347.8M | $364.2M |
| Operating income | −$92.9M | −$82.4M | −$254.9M | −$411.0M | −$544.4M | −$564.7M | −$443.6M | −$436.3M |
| EBITDA | −$75.8M | −$54.9M | −$225.1M | −$359.6M | −$614.9M | −$433.3M | −$390.1M | −$373.9M |
| Net income | −$85.1M | −$75.7M | −$253.8M | −$405.7M | −$654.6M | −$479.4M | −$436.4M | −$416.3M |
| Net margin | -93.8% | -35.3% | -88.5% | -108.6% | -145.6% | -85.0% | -59.0% | -42.4% |
| EPS (diluted) | -1.00 | -0.75 | -2.53 | -3.80 | -6.41 | -4.28 | -3.56 | -3.32 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1.3B | $-2.88 | $-3.16–$-2.53 | 12 |
| 2027 | $1.7B | $-1.86 | $-4.18–$3.30 | 12 |
| 2028 | $2.2B | $-0.10 | $-0.24–$0.07 | 8 |
| 2029 | $2.9B | $1.80 | $1.74–$1.94 | 6 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Guardant Health, Inc. Common Stock
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
www.guardanthealth.com- Employees
- 2,506
- IPO / List date
- Oct 4, 2018
- HQ
- PALO ALTO, CA
Held by traders on TradeandTell
No one on the platform currently holds GH.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 337,600 | $31.2M |
| Bridgewater Associatesas of 2026-03-31 | 13,351 | $1.2M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded GH yet.
